Evolent Health (EVH) to Release Earnings on Thursday

Evolent Health (NYSE:EVH - Get Free Report) will be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.30 per share for the quarter. Evolent Health has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Individual that wish to listen to the company's earnings conference call can do so using this link.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.09. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. The firm had revenue of $647.10 million for the quarter, compared to the consensus estimate of $636.46 million. During the same quarter in the prior year, the company posted $0.06 earnings per share. The company's revenue for the quarter was up 37.9% compared to the same quarter last year. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Evolent Health Stock Performance

Shares of NYSE:EVH traded down $0.78 on Thursday, hitting $23.36. 1,325,000 shares of the company were exchanged, compared to its average volume of 1,620,588. The stock's 50 day moving average price is $28.17 and its 200 day moving average price is $25.20. Evolent Health has a 1-year low of $17.98 and a 1-year high of $35.00. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $2.71 billion, a P/E ratio of -18.68 and a beta of 1.56.

Insider Buying and Selling at Evolent Health

In other news, CEO Seth Blackley sold 187,904 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the transaction, the chief executive officer now directly owns 411,924 shares in the company, valued at $12,357,720. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Evolent Health news, President Daniel Joseph Mccarthy sold 23,693 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.89, for a total transaction of $731,876.77. Following the transaction, the president now directly owns 198,809 shares of the company's stock, valued at $6,141,210.01. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley sold 187,904 shares of the firm's stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the sale, the chief executive officer now owns 411,924 shares of the company's stock, valued at $12,357,720. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 307,291 shares of company stock worth $9,290,385. Corporate insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EVH. KeyCorp began coverage on Evolent Health in a research report on Friday, October 11th. They issued an "overweight" rating and a $35.00 target price on the stock. Truist Financial reaffirmed a "buy" rating and set a $33.00 price objective on shares of Evolent Health in a research note on Tuesday, August 27th. JMP Securities dropped their price target on shares of Evolent Health from $34.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Friday, August 9th. Stephens reissued an "overweight" rating and set a $42.00 target price on shares of Evolent Health in a research note on Tuesday, July 30th. Finally, Citigroup dropped their target price on Evolent Health from $35.00 to $33.00 and set a "buy" rating on the stock in a research report on Tuesday. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $38.60.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.